Tempest Therapeutics
Update in progressTPST (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule cancer therapies. Its lead candidates are Amezalpat, an oral selective PPARα antagonist for first-line unresectable or metastatic hepatocellular carcinoma, which completed Phase 2, and TPST-1495, a dual EP2/EP4 receptor antagonist targeting prostaglandin E2 for various cancers. The company has a Roche collaboration to advance Amezalpat in a global first-line trial and is headquartered in Brisbane, California.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!